Cargando…

What can we learn from phase II adjuvant trials in melanoma?

Detalles Bibliográficos
Autores principales:	Keilholz, U, Suciu, S, Eggermont, A M M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374544/ https://www.ncbi.nlm.nih.gov/pubmed/10883660 http://dx.doi.org/10.1054/bjoc.2000.1277

Ejemplares similares

Publication of clinical trial protocols – what can we learn?
por: Skogvoll, Eirik, et al.
Publicado: (2013)

What is changing in the adjuvant treatment of melanoma?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054
por: Eggermont, Alexander, et al.
Publicado: (2022)

Neuroblastoma Mass Screening—What Can We Learn From It?
por: Katanoda, Kota
Publicado: (2016)

Psychosis breakthrough on antipsychotic maintenance medication (BAMM): what can we learn?
por: Rubio, Jose M., et al.
Publicado: (2017)

Pressure is not a privilege: what we can learn from Simone Biles
por: Tardelli, Vitor S., et al.
Publicado: (2021)

Adjuvant therapy for high-risk melanoma
por: Eggermont, Alexander M.M.
Publicado: (2013)

Pearls collections: What we can learn about infectious disease and cancer
por: Knoll, Laura J., et al.
Publicado: (2018)

Editorial: Clustering of Schizophrenia With Other Comorbidities—What Can We Learn?
por: Mitchell, Braxton D.
Publicado: (2009)

More Evidence on the Effects of Deworming: What Lessons Can We Learn?
por: Croke, Kevin, et al.
Publicado: (2017)

Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
por: Kaufmann, Horacio
Publicado: (2017)

Lessons learned from COVID-19 for clinical research operations in Italy: what have we learned and what can we apply in the future?
por: Cagnazzo, Celeste, et al.
Publicado: (2020)

The Future of Pathology: What can we Learn from the COVID-19 Pandemic?
por: Williams, Bethany J, et al.
Publicado: (2020)

What can we learn from smart-pump infusion data analysis?
por: Litman, Ronald S., et al.
Publicado: (2020)

The challenge of the COVID-19 pandemic: what can we learn from history?
por: dos Santos, Vanessa Prado
Publicado: (2021)

Surgery: To what extent can we operate?
por: Kakeji, Yoshihiro
Publicado: (2018)

What can we learn from studies on regional differences in the utilization of laboratory tests?
por: Larsson, Anders
Publicado: (2011)

We can do much better than what we did
por: Lee, Sang-Hak
Publicado: (2020)

Individualized Treatment Effects: Machine Learning Can Revolutionize Observations, but Let’s Understand What We Are Observing
por: Mosier, Jarrod M.
Publicado: (2023)

The FIRE AND ICE Trial: What We Know, What We Can Still Learn, and What We Need to Address in the Future
por: Kuck, Karl‐Heinz, et al.
Publicado: (2018)

Adjuvant interferon in the treatment of melanoma
por: Middleton, M R
Publicado: (1999)

GOAL: What Have We Learned?
por: Leek, Timothy K Vander
Publicado: (2005)

What we learn in time of pestilence
por: Ellaway, Rachel, et al.
Publicado: (2020)

Bronchiectasis Management in China, What We Can Learn from European Respiratory Society Guidelines
por: Wang, Ning, et al.
Publicado: (2018)

Incontinentia pigmenti: What we know and can we manage it as retinopathy of prematurity?
por: Al-Farsi, Nouf, et al.
Publicado: (2022)

Racism in science: what can we do about it?
Publicado: (2020)

The best pharmaceuticals for children—what can we do?
por: Li, Hao, et al.
Publicado: (2020)

Review and publication of protocol submissions to Trials – what have we learned in 10 years?
por: Li, Tianjing, et al.
Publicado: (2016)

Adjuvant chemotherapy in older women (ACTION) study – what did we learn from the pilot phase?
por: Leonard, R, et al.
Publicado: (2011)

Learning from successes: designing medication adherence intervention research so that we can learn what works and why
por: Garfield, Sara, et al.
Publicado: (2022)

The COVID-19 challenge. What have we learned?
por: Ceccato, Adrian, et al.
Publicado: (2022)

Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?
por: Thebault, Eric, et al.
Publicado: (2021)

Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't
por: Ong, Albert C M, et al.
Publicado: (2022)

Adjuvant interferon in melanoma – a resurrection?
por: Middleton, M R, et al.
Publicado: (2001)

Time-restricted feeding: what we have done and what more we can do?
por: Sun, Yuning, et al.
Publicado: (2023)

What Do We Know about Suicide Bereavement, and What We Can Do to Help Suicide-Loss Survivors?
por: Levi-Belz, Yossi, et al.
Publicado: (2023)

Bidding farewell to 2020: what lessons have we learned and what can bioethics continue to teach us?
por: Laurie, Graeme T.
Publicado: (2020)

Bladder Neck Reconstruction in Radical Prostatectomy: What we still can learn and improve?
por: Favorito, Luciano A.
Publicado: (2015)

The role of the patient in patient safety: What can we learn from healthcare’s history?
por: Leistikow, Ian, et al.
Publicado: (2018)

COVID-19: what have we learned?
por: Ho, Yeh-Li, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j70q40uhmpdf4dhcl830rk63fs